Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-12-02 , DOI: 10.1016/s1470-2045(24)00647-8

In April, 2021, The Lancet Oncology published results of the phase 2 BYLieve study on alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer.¹

中文翻译：

撤回和重新发布——Alpelisib 联合氟维司群治疗 CDK4/6 抑制剂后 PIK3CA 突变的激素受体阳性晚期乳腺癌（BYLieve）：2 期、多中心、开放标签、非对照研究的一个队列

2021 年 4 月，《柳叶刀·肿瘤学》发表了 alpelisib 联合氟维司群治疗 PIK3CA 突变、激素受体阳性晚期乳腺癌的 2 期 BYLieve 研究结果。¹

更新日期：2024-12-03

点击分享查看原文

点击收藏

阅读更多本刊新发论文